Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma

Gastric Adenocarcinoma Clinical Trial

Official title:

Phase 2 Study of Trastuzumab Deruxtecan (T-DXd) in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05034887
• Other study ID #: EPOC2003
• Status: Recruiting
• Phase: Phase 2
• Start date: January 31, 2022
• Est. completion date: March 31, 2025

Study information

• Verified date: April 2022
• Source: National Cancer Center Hospital East
• Contact: Kohei Shitara, MD
• Phone: +81-4-7133-1111
• Email: T-DXd_NAC_core[@]east.ncc.go.jp
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open-label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of neoadjuvant chemotherapy with T-DXd monotherapy in patients with HER2-positive gastric cancer.

Description:

This study is an open-label, single-arm, multicenter, phase 2 clinical trial. Eligible patients are with previously untreated gastric and gastroesophageal junction adenocarcinoma as defined by cT2-4 and/or cN+ without evidence of metastatic disease. Study treatment in this study is neoadjuvant treatment with the investigational drug, T-DXd alone, followed by surgery. T-DXd will be administered at a dose of 6.4 mg/kg (decimal) by intravenous infusion every 21 days (3 weeks) for 3 cycles as the neoadjuvant treatment followed by surgery.

The analyses will be performed on the following 2 cohorts:

• Gastric cancer or gastroesophageal junction cancer with HER2 overexpression (IHC3+, or IHC2+ and ISH positive [FISH or DISH]) (Primary cohort)

• Gastric or gastroesophageal junction cancer patients with HER2 low expression (IHC1+, or IHC2+ and ISH-negative [FISH or DISH]) and HER2-ECD > 11.6 ng/mL (Exploratory cohort)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 37
• Est. completion date: March 31, 2025
• Est. primary completion date: March 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction.

2. Has HER2 overexpression (IHC3+, or IHC2+ and ISH positive [FISH or DISH]). (HER2 Low expression: IHC1+, or IHC2+ and ISH-negative [FISH or DISH] with HER2-ECD > 11.6 ng/mL in the exploratory cohort).

3. Have previously untreated gastric and gastroesophageal junction adenocarcinoma and cT2-4 and/or cN+M0.according to the UICC TNM classification (8th edition),

4. Age = 20 years as the day of informed consent.

5. Has an ECOG performance status (PS) of 0 or 1.

6. Has a left ventricular ejection fraction (LVEF) = 50% by either echocardiogram (ECHO) or multigated collecting acquisition (MUGA) scan within 28 days before enrollment (acceptable on the same day of the week).

7. Has a corrected QT interval (QTc) ? 470 ms in females, or QTc ? 450 ms in males based on a 12-lead ECG screening within 28 days before enrollment (allowed on the same day of the week). [Fridericia's correction is recommended]

8. Satisfies all of the following requirements within 14 days before enrollment (allowed on the same day of the week).

• Absolute neutrophil count ?1500 / mm3 [except for assessment ? 14 days after administration of Granules colony-stimulating factors (G-CSF)]

• Hemoglobin ? 8.0 g/dL (except for those measured within 7 days after whole blood transfusion or packed red blood cells)

• Platelet count ?100000 per mm3 (excluding measurements within 7 days after platelet transfusion).

• Total bilirubin ?1.5 mg/dL (patients with gilbert's syndrome will be allowed if they have < 3.0 mg/dL).

• AST(GOT)?100 IU/L

• ALT(GPT)?100 IU/L

• Serum albumin ? 2.5 g/dL

• Calculated creatinine clearance (Cockcroft-Gault *) or the actual value ? 30 mL/min

• Cockcroft-Gault equation: creatinine clearance= (140 - age) × body weight (kg) / (72 × Serum creatinine) (* 0.85 x the value obtained for females).

• PT(INR)< 1.8

• aPTT < 60 seconds

9. Has a treatment-free period from the end of pre-treatment to before enrollment (allowed on the same day of the week), defined as:

i. Surgery with general anesthesia : ? 4 weeks ii. Radiotherapy: ? 4 weeks (including palliative stereotactic body radiation therapy to the chest; palliative stereotactic body radiation therapy to other than the chest ? 2 weeks; abdominal vertebral bodies should be included in the abdomen).

iii. Chloroquine and hydroxychloroquine : ? 15 days

10. Has a prior radiotherapy or surgical AE recovered of ? Grade 1 or ? baseline on CTCAE v5.0. However, this shall not apply to events where the symptoms are stable even if they are grade 2 or higher.

11. Female of childbearing potential have a negative pregnancy test within 7 days before enrollment (allowed on the same day of the week). Male and Female of childbearing potential agree to contraception for a period (4 months for male and 7 months for Female) from informed consent to the last dose of study drug (see 4.3 "Pregnancy and contraception").

12. Written informed consent of participation in the study has been obtained from the patient.

Exclusion Criteria:

1. Has a medical history of myocardial infarction or congestive heart failure (New York Heart Association Classes II-IV) within 6 months before enrollment, corresponding to the value diagnosed as myocardial infarction as defined by the *validated test within 28 days before enrollment (allowed on the same day), unstable angina, or any serious arrhythmia requiring treatment.

• tested in local institutions **: Enrollment is allowed with value exceeds ULN if myocardial infarction can be excluded.

2. Active other cancers [Synchronous other cancers and metachronous other cancers within 3 years prior to enrollment, but carcinoma in situ or other lesions corresponding to mucosal carcinoma that are considered curable with local treatment will not be included in active other cancers.]

3. Has serious (hospitalized) complications (intestinal palsy, intestinal obstruction, pulmonary fibrosis, diabetes mellitus that is difficult to control, heart failure, myocardial infarction, unstable angina, renal failure, liver failure, psychiatric disorders, cerebrovascular disorders, etc.).

4. Has history of gastrointestinal perforation and/or gastrointestinal fistula within 6 months before enrollment.

5. Has any of the following infections:

• HBs antigen positive

• HBs antibody or HBc antibody and HBV-DNA positive

• Active hepatitis C (eg, if HCV RNA is detected qualitatively) Patients who are HBsAg positive but who have achieved HBV DNA level < 1.3 log IU/mL (2.1 log copies/mL) after treatment with antiviral drugs such as NAs, are eligible for the study.

6. HIV infection

7. Lung diseases defined as:

• Has a history of non-infectious interstitial lung disease or pneumonitis that required treatment, has interstitial lung disease or pneumonitis, or these lung diseases cannot be ruled out by radiographic examination before enrollment.

• Severe pulmonary disease (eg, pulmonary embolism within 3 months prior to enrollment, serious bronchial asthma, severe COPD, restrictive pulmonary disease, or pleural effusion).

Lung-related autoimmune or connective tissue or inflammatory diseases (eg, rheumatoid arthritis, Sjögren's syndrome, or sarcoidosis) with clinically severe pulmonary risks.

• Has history of pneumonectomy.

8. Has history of concomitant autoimmune disease or chronic or recurrent autoimmune disease.

9. Administration of systemic corticosteroids (except prophylactic administration for diagnostic tests or allergic reactions, and temporary use for the purpose of reducing edema associated with radiotherapy) or immunosuppressants is required, or has received these treatments within 14 days before enrollment in the study.

10. Has unhealed wounds, ulcers, or fractures.

11. If patients are a pregnancy or breastfeeding patient.

12. Has documented severe hypersensitivity to study drug active ingredients or additives.

13. Has history/complications of severe hypersensitivity reactions to other monoclonal antibodies.

14. has uncontrolled acute systemic infection that requires Infusion intravenous antibiotic, antiviral, or antifungal drug.

15. Unwilling or unable to follow study protocol or any of the instructions by the physician.

16. The investigator or subinvestigator considered it ineligible for the study.

Related Conditions & MeSH terms

• Adenocarcinoma
• Esophageal Neoplasms
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Intervention

Drug:
• Trastuzumab Deruxtecan (T-DXd)
T-DXd will be administered at a dose of 6.4 mg/kg (decimal) by intravenous infusion every 21 days (3 weeks) for subsequent three cycles.

Locations

Country	Name	City	State
Japan	National Cancer Center Hospital East	Kashiwa	Chiba

Sponsors (2)

Lead Sponsor	Collaborator
National Cancer Center Hospital East	Daiichi Sankyo Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Biomarkers in the Primary cohort and the Exploration cohort	Change of ctDNA and examination of various biomarkers.	6 months
Other	MPR rate determined by investigator assessment in the Exploration cohort	The proportion of subjects with< 10% residual tumor in the stomach and lymph nodes	6 months
Other	pCR rate determined by investigator assessment in the Exploration cohort	The proportion of subjects with complete remission of gastric and lymph node tumors	6 months
Other	Curative Resection Rate in the Exploration Part	Defined as the proportion of subjects who start study treatment and undergo radical resection (R0).	6 months
Other	AE rate in the Exploration Part	The treatment-emergent AEs will be summarized by CTCAE v5.0	From the start day of study treatment, "47 days after the last dose, 30 days after surgery, or if postoperative adjuvant chemotherapy or treatment is started before it, whichever comes first.
Primary	Major pathological response [MPR] rate: by central assessment	MPR is defined as the proportion of subjects with < 10% residual tumor in the stomach and lymph nodes by central assessment	6 months
Secondary	MPR rate determined by the local assessment	The proportion of subjects with MPR by Local assessment	6 months
Secondary	Pathological complete response (pCR) rate	The proportion of subjects with complete remission of gastric and lymph node tumors by local assessment	6 months
Secondary	Curative Resection Rate	Defined as the proportion of subjects who start study treatment and undergo radical resection (R0)	6 months
Secondary	AE rate	The treatment-emergent AEs will be summarized by CTCAE v5.0.	From the start day of study treatment, "47 days after the last dose, 30 days after surgery, or if postoperative adjuvant chemotherapy or treatment is started before it, whichever comes first.